Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Michael McCaughan

Michael McCaughan has has 25 years of experience providing analysis and insight about the biopharma industry, including 10 years as Editor-In-Chief of The Pink Sheet and The Pink Sheet DAILY. He speaks frequently on regulatory and policy developments affecting the industry.

Latest From Michael McCaughan

US FDA Pediatric Priority Review Voucher Renewal May Come With Strings Attached

Legislation to allow the US FDA to continue awarding pediatric rare disease PRVs is moving forward, but has become the subject of partisan disagreements amid calls for new mandatory study authorities to “balance” the program.

Rare Diseases Legislation

Brand Drug Shortages Complicate US FDA Messaging To Congress

The US FDA is eager for Congress to address critical factors contributing to chronic generic drug shortages, but elected officials often are more focused on special cases like obesity drugs and ADHD treatment where the answers are very different. 

Generic Drugs Manufacturing

Patient Input In US Medicare Price Negotiation: Will CMS Close The Door?

The US Medicare agency is planning to modify its patient input process for feedback on products selected for price cuts in the program’s second year. The list of options includes holding the meetings in less public settings.

Medicare Pricing Debate

Need Advice About Advisory Committees, US FDA? Try Having Some

FDA’s drug center has all but stopped holding meetings at this point, which begs the question: why do they want advice on how to make them better?

Advisory Committees Prescription To OTC Switch

US FDA Wants Advice About Advisory Committees: Try Having Some?

The FDA’s drug center has all but stopped holding meetings at this point, which begs the question: why do they want advice on how to make them better?

Advisory Committees Drug Review

First Do No Harm: US MedPAC Wrestles With Complexity Of Low-Cost Drug Pricing

The US Medicare Payment Advisory Commission is analyzing two of the lower-cost segments of the US medicine marketplace: generic drugs and the 340B brand discount program. In both cases, there is a picture of complexity and unintended consequences to rival higher cost segments.

Medicare Pricing Debate
See All
UsernamePublicRestriction

Register